Achieve Life Sciences presents 52-week cytisinicline safety data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
May 19, 2026 2:15 PM EDTORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA
No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure
Nausea a common barrier to treatment adherence with smoking cessation therapies was reported in only 2.5% of participants over 52 weeks of continuous exposure¹
SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization... More
